ライブラリ登録: Guest
Begell Digital Portal Begellデジタルライブラリー 電子書籍 ジャーナル 参考文献と会報 リサーチ集
Critical Reviews™ in Immunology
インパクトファクター: 1.352 5年インパクトファクター: 3.347 SJR: 0.657 SNIP: 0.55 CiteScore™: 2.19

ISSN 印刷: 1040-8401
ISSN オンライン: 2162-6472

巻:
巻 39, 2019 巻 38, 2018 巻 37, 2017 巻 36, 2016 巻 35, 2015 巻 34, 2014 巻 33, 2013 巻 32, 2012 巻 31, 2011 巻 30, 2010 巻 29, 2009 巻 28, 2008 巻 27, 2007 巻 26, 2006 巻 25, 2005 巻 24, 2004 巻 23, 2003 巻 22, 2002 巻 21, 2001 巻 20, 2000 巻 19, 1999 巻 18, 1998 巻 17, 1997 巻 16, 1996 巻 15, 1995 巻 14, 1994

Critical Reviews™ in Immunology

DOI: 10.1615/CritRevImmunol.v21.i1-3.90
13 pages

Dendritic Cells in Cancer Immunotherapy

Matthias Gunzer
Department of Dermatology, University of Munster, Germany
Stephan Grabbe
Department of Dermatology, University of Munster, Germany

要約

Antigen presentation is a critical regulatory element for the induction of cellular immune responses. Thus, one of the principal current goals of tumor immunotherapy is to control and enhance tumor antigen presentation. In this respect, dendritic cells (DC) are now being widely investigated as immunotherapeutic agents for the treatment of disseminated malignancies. At present, numerous ways to employ DCs for tumor immunotherapy are being tested, ranging from direct in situ expansion and activation of DCs to adoptive transfer of ex vivo generated DCs, and numerous techniques have been designed to optimize DC activation, tumor antigen delivery to DCs, and induction of tumor-specific, as well as helper immune responses, in vivo. However, the results of recent preclinical studies and the diversity of the clinical phase I trials that are currently underway indicate that little is still known about the exact mechanisms by which DCs modulate tumor immunity and pose the concern that premature clinical trials might not yield the desired results and might be harmful to, rather than promote, the concept of DC-based tumor immunotherapy. This review summarizes some of the current approaches to induce tumor immunity by DC-based vaccination and discusses their advantages and concerns.


Articles with similar content:

Therapeutic Dendritic Cell−Based Cancer Vaccines: The State of the Art
Critical Reviews™ in Immunology, Vol.33, 2013, issue 6
Marius M. Strioga, Valerijus Ostapenko, Daniel J. Powell Jr., Neringa T. Dobrovolskiene, Virgil E. J. C. Schijns, Thomas Felzmann, Jaroslav Michalek, Miroslava Matuskova
Victory and Defeat in the Induction of a Therapeutic Response through Vaccine Therapy for Human and Canine Brain Tumors: A Review of the State of the Art
Critical Reviews™ in Immunology, Vol.34, 2014, issue 5
Nate N. Waldron , G Elizabeth Pluhar, Rob Shaver, Brian M. Andersen, Michael R. Olin, Christopher L. Moertel
Interleukin 35−Producing B Cells (i35-Breg): A New Mediator of Regulatory B-Cell Functions in CNS Autoimmune Diseases
Critical Reviews™ in Immunology, Vol.35, 2015, issue 1
Charles E. Egwuagu, Cheng-Rong Yu
Role of Dendritic Cells in Host−Mycobacterium Bovis BCG Interactions
Forum on Immunopathological Diseases and Therapeutics, Vol.6, 2015, issue 3-4
Krzysztof Krawczyk, Magdalena Kowalewicz-Kulbat, Wieslawa Rudnicka
Current Vaccination Strategies for the Treatment of B-Cell Lymphoma and Multiple Myeloma
Critical Reviews™ in Immunology, Vol.29, 2009, issue 5
Nurit Hollander